StockpollyBeta
Get App
Popularity #2,121
GLUE · NASDAQ · Biotechnology

Monte Rosa Therapeutics (GLUE)

Develops molecular glue degrader medicines across oncology, immunology, and inflammation.

$11.75
vs last close−0.86 (−6.79%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0015961852313349
Cost of revenue002200000020
Gross profit00−13961852313329
373534353648413946525258
Research & development282725262839323137424448
989989989111010
General & administrative989989989111010
Other expenses0000000000−20
Operating income−37−35−35−33−271344−16−33−50−50−49
223333443466
Interest income222333333466
Other non-operating income0−2−3−3−3−3−4−4−3−4−6−6
Income before tax−35−33−32−30−241648−11−30−46−44−43
Income tax expense00000211−3000
Net income from continuing operations−35−33−32−30−241347−12−27−46−45−43
Other adjustments000000000000
Net income−35−33−32−30−241347−12−27−46−45−43
EPS, basic−$0.70−$0.58−$0.53−$0.43−$0.29$0.22$0.57−$0.20−$0.44−$0.70−$0.53−$0.51
EPS, diluted−$0.70−$0.58−$0.53−$0.43−$0.29$0.22$0.57−$0.20−$0.44−$0.70−$0.53−$0.51
Weighted average shares, basic505760718261826262668485
Weighted average shares, diluted505760718261836262668485
EBITDA−35−31−30−28−221850−9−28−44−42−41
Depreciation & amortization222222222222
EBIT−37−33−32−30−241648−11−30−46−44−43